New hope for tough ovarian cancer: CBX-12 trial launches

NCT ID NCT06315491

Recruiting now Disease control Sponsor: Cybrexa Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug, CBX-12, in 40 women with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if CBX-12 can shrink tumors and how safe it is at two different dose levels given every three weeks. Participants must have a specific type of ovarian, fallopian tube, or primary peritoneal cancer that is resistant or refractory to prior treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL HIGH-GRADE SEROUS CANCER OF THE OVARY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian carcinoma ovarian serous adenocarcinoma primary peritoneal carcinoma refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLATINUM-RESISTANT OVARIAN CANCER REFRACTORY OVARIAN CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Albert Einstein College of Medicine Montefiore Medical
ACTIVE_NOT_RECRUITING

New York, New York, 10021, United States
Allegheny Singer Research Institute D/B/A Ahn Research Institution
RECRUITING

Pittsburgh, Pennsylvania, 15212, United States

Contact Phone: •••-•••-••••
Arizona Oncology Associates
ACTIVE_NOT_RECRUITING

Tucson, Arizona, 85711, United States
D&H Cancer Research Center
ACTIVE_NOT_RECRUITING

Margate, Florida, 33063, United States
Honor Health
WITHDRAWN

Scottsdale, Arizona, 85260, United States
Mary Crowley Cancer Research
RECRUITING

Dallas, Texas, 75251, United States

Contact Phone: •••-•••-••••
Multicare Institute For Research & Innovation
ACTIVE_NOT_RECRUITING

Tacoma, Washington, 98405, United States
Northwest Cancer Centers
WITHDRAWN

Dyer, Indiana, 46311, United States
Norton Cancer Institute
ACTIVE_NOT_RECRUITING

Louisville, Kentucky, 40202, United States
Oncology Associates of Oregon
ACTIVE_NOT_RECRUITING

Eugene, Oregon, 97401, United States
Pci Nyu Langone Health
ACTIVE_NOT_RECRUITING

New York, New York, 10016, United States
South Florida Gynecology
ACTIVE_NOT_RECRUITING

Tampa, Florida, 33606, United States
Texas Oncology- Gulf Coast
ACTIVE_NOT_RECRUITING

The Woodlands, Texas, 77380, United States
University Hospitals Seidman Cancer Center
ACTIVE_NOT_RECRUITING

Cleveland, Ohio, 44106, United States
Usc Norris Comprehensive Cancer Center
ACTIVE_NOT_RECRUITING

Los Angeles, California, 90033, United States
Women's Cancer Care
ACTIVE_NOT_RECRUITING

Covington, Louisiana, 70433, United States
Yale University School of Medicine
ACTIVE_NOT_RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.